[go: up one dir, main page]

WO2000018961A3 - Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer - Google Patents

Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer Download PDF

Info

Publication number
WO2000018961A3
WO2000018961A3 PCT/US1999/022535 US9922535W WO0018961A3 WO 2000018961 A3 WO2000018961 A3 WO 2000018961A3 US 9922535 W US9922535 W US 9922535W WO 0018961 A3 WO0018961 A3 WO 0018961A3
Authority
WO
WIPO (PCT)
Prior art keywords
hrpca
prostate cancer
androgen
treatment
diagnosis
Prior art date
Application number
PCT/US1999/022535
Other languages
French (fr)
Other versions
WO2000018961A2 (en
Inventor
Kyle J Macbeth
Andrew W Shyjan
Original Assignee
Millennium Pharm Inc
Kyle J Macbeth
Andrew W Shyjan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/163,759 external-priority patent/US6872811B1/en
Application filed by Millennium Pharm Inc, Kyle J Macbeth, Andrew W Shyjan filed Critical Millennium Pharm Inc
Priority to AU65021/99A priority Critical patent/AU6502199A/en
Priority to EP99952976A priority patent/EP1117836A2/en
Priority to JP2000572408A priority patent/JP2002531061A/en
Priority to CA002344550A priority patent/CA2344550A1/en
Publication of WO2000018961A2 publication Critical patent/WO2000018961A2/en
Publication of WO2000018961A3 publication Critical patent/WO2000018961A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention is based in part on the discovery of a number of genes (HRPCa 2, HRPCa 3, HRPCa 6/7, HRPCa 8, HRPCa 9, HRPCa 10, HRPCa 13, HRPCa 14, HRPCa 15, and HRPCa 19) which are androgen-inducible in androgen-dependent prostate cancer (e.g., LNCaP cells) cells and constitutively expressed in androgen-independent prostate cancer cells (e.g., LN3 LNCaP cells). Because androgen is required for growth and survival of androgen-dependent prostate cancer cells, HRPCa 2, HRPCa 3, HRPCa 6/7, HRPCa 8, HRPCa 9, HRPCa 10, HRPCa 13, HRPCa 14, HRPCa 15, and HRPCa 19 are therapeutic targets. An agent which decreases the expression or activity of HRPCa 2, HRPCa 3, HRPCa 6/7, HRPCa 8, HRPCa 9, HRPCa 10, HRPCa 13, HRPCa 14, HRPCa 15, or HRPCa 19 may slow or arrest the growth of prostate cancer cells or may kill prostate cancer cells. Moreover, because the genes of the invention are constitutively expressed by androgen-independent prostate cancer cells, they can be used to identify agents useful for the treatment of androgen-dependent and androgen-independent prostate cancer.
PCT/US1999/022535 1998-09-30 1999-09-30 Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer WO2000018961A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU65021/99A AU6502199A (en) 1998-09-30 1999-09-30 Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
EP99952976A EP1117836A2 (en) 1998-09-30 1999-09-30 Expressionanalysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
JP2000572408A JP2002531061A (en) 1998-09-30 1999-09-30 Expression analysis of specific nucleic acids and polypeptides useful in diagnosis and treatment of prostate cancer
CA002344550A CA2344550A1 (en) 1998-09-30 1999-09-30 Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16415998A 1998-09-30 1998-09-30
US09/164,159 1998-09-30
US09/163,759 US6872811B1 (en) 1998-09-30 1998-09-30 HRPCa9 and HRPCa10 nucleic acids and polypeptides
US09/163,759 1998-10-30

Publications (2)

Publication Number Publication Date
WO2000018961A2 WO2000018961A2 (en) 2000-04-06
WO2000018961A3 true WO2000018961A3 (en) 2001-03-08

Family

ID=26859918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/022535 WO2000018961A2 (en) 1998-09-30 1999-09-30 Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer

Country Status (5)

Country Link
EP (1) EP1117836A2 (en)
JP (1) JP2002531061A (en)
AU (1) AU6502199A (en)
CA (1) CA2344550A1 (en)
WO (1) WO2000018961A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960474B2 (en) 2000-06-28 2005-11-01 Bristol-Myers Squibb Company Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
DK1109937T3 (en) 1998-09-02 2009-03-09 Diadexus Inc Procedures for diagnosis, monitoring, staging and imaging for various cancers
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US6355430B1 (en) 1998-12-24 2002-03-12 Millennium Pharmaceuticals, Inc. Diagnostic and screening methods employing KIAA0101
WO2000065067A2 (en) * 1999-04-23 2000-11-02 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
DE60138465D1 (en) * 2000-07-12 2009-06-04 Agensys Inc NEW TUMOR ANTIGEN THAT CAN BE USED FOR DIAGNOSIS AND THERAPY OF BUBBLE, ICE STICK, LUNG AND KIDNEY CANCER
EP2316976A1 (en) 2000-11-28 2011-05-04 Wyeth LLC Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2002044419A2 (en) 2000-11-28 2002-06-06 Wyeth Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2007033187A2 (en) 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
EP2171094B1 (en) 2007-07-06 2011-11-16 The Regents of the University of Michigan Mipol1-etv1 gene rearrangements
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
CA2774349C (en) 2009-09-17 2019-03-19 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
JP2012196211A (en) * 2012-04-10 2012-10-18 Japan Science & Technology Agency Prostatic cancer marker polypeptide, antibody to the same, and method for diagnosing prostatic cancer using the same

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028498A1 (en) * 1994-04-15 1995-10-26 The Trustees Of Columbia University In The City Of New York Method for molecular staging of prostate cancer
WO1997027317A1 (en) * 1996-01-23 1997-07-31 Affymetrix, Inc. Nucleic acid analysis techniques
WO1997036535A2 (en) * 1996-03-29 1997-10-09 Board Of Regents, The University Of Texas System Biomarkers for detection, diagnosis and prognosis of prostate cancer
WO1998004689A1 (en) * 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
WO1998005797A1 (en) * 1996-08-06 1998-02-12 Cell Genesys, Inc. Prostate cancer drug screening
US5786362A (en) * 1994-06-16 1998-07-28 University Of Miami Method of treating Hormone independent cancer
WO1998039447A1 (en) * 1997-03-07 1998-09-11 Diagnostic Products Corporation Prostate cancer-specific marker

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028498A1 (en) * 1994-04-15 1995-10-26 The Trustees Of Columbia University In The City Of New York Method for molecular staging of prostate cancer
US5786362A (en) * 1994-06-16 1998-07-28 University Of Miami Method of treating Hormone independent cancer
WO1998004689A1 (en) * 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
WO1997027317A1 (en) * 1996-01-23 1997-07-31 Affymetrix, Inc. Nucleic acid analysis techniques
WO1997036535A2 (en) * 1996-03-29 1997-10-09 Board Of Regents, The University Of Texas System Biomarkers for detection, diagnosis and prognosis of prostate cancer
WO1998005797A1 (en) * 1996-08-06 1998-02-12 Cell Genesys, Inc. Prostate cancer drug screening
WO1998039447A1 (en) * 1997-03-07 1998-09-11 Diagnostic Products Corporation Prostate cancer-specific marker

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BIECHE I ET AL: "Overexpression of the stathmin gene in a subset of human breast cancer.", BRITISH JOURNAL OF CANCER, vol. 78, no. 6, 1998, pages 701 - 709, XP000939150, ISSN: 0007-0920 *
BLOK L J ET AL: "ISOLATION OF CDNAS THAT ARE DIFFERENTIALLY EXPRESSED BETWEEN ANDROGEN-DEPENDENT AND ANDROGEN-INDEPENDENT PROSTATE CARCINOMA CELLS USING DIFFERENTIAL DISPLAY PCR", PROSTATE,US,WILEY-LISS, NEW YORK, NY, vol. 26, no. 4, 1 April 1995 (1995-04-01), pages 213 - 224, XP000611577, ISSN: 0270-4137 *
CHANG GLENN T G ET AL: "Differentially expressed genes in androgen-dependent and -independent prostate carcinomas.", CANCER RESEARCH, vol. 57, no. 18, 1997, pages 4075 - 4081, XP002147425, ISSN: 0008-5472 *
DELWORTH MARK G ET AL: "Systemic administration of 4-amidinoindanon-1-(2'-amidino)-hydrazone, a new inhibitor of S-adenosylmethionine decarboxylase, produces cytostasis of human prostate cancer in athymic nude mice.", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 6, no. 2, 1995, pages 293 - 299, XP000946083, ISSN: 1019-6439 *
FRIEDRICH ET AL.: "DIFFERENTIATION-STAGE SPECIFIC EXPRESSION OF ONCOPROTEIN 18 IN HUMAN AND RAT PROSTATIC ADENOCARCINOMA", THE PROSTATE, vol. 27, 1995, pages 102 - 109, XP000938476 *
GREGORY ET AL.: "ANDROGEN RECEPTOR EXPRESSION IN ANDROGEN-INDEPENDENT PROSTATE CANCER IS ASSOCIATED WITH INCREASED EXPRESSION OF ANDROGEN-REGULATED GENES", CANCER RESEARCH, vol. 58, December 1998 (1998-12-01), pages 5718 - 5724, XP002147396 *
JORDAN MARY ANN ET AL: "Microtubules and actin filaments: Dynamic targets for cancer chemotherapy.", CURRENT OPINION IN CELL BIOLOGY, vol. 10, no. 1, February 1998 (1998-02-01), pages 123 - 130, XP000939151, ISSN: 0955-0674 *
PRASAD ET AL.: "DIFFERENTIAL EXPRESSION OF STATHMIN DURING NEOPLASTIC CONVERSION OF HUMAN PROSTATE EPITHELIAL CELLS IS REVERSED BY HYPOMETHYLATING AGENT, 5-AZACYTIDINE", INT.J.ONCOLOGY, vol. 14, March 1999 (1999-03-01), pages 529 - 534, XP000939152 *
ROBSON C N ET AL: "IDENTIFICATION OF PROSTATIC ANDROGEN REGULATED GENES USING THE DIFFERENTIAL DISPLAY TECHNIQUE", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH,US,PHILADELPHIA, AACR, vol. MEETING 86, 18 March 1995 (1995-03-18), pages 266, XP002019344, ISSN: 0197-016X *
YANG ET AL.: "IDENTIFICATION OF GENES EXPRESSED DIFFERENTIALLY BY LNCaP OR PC-3 PROSTATE CANCER CELL LINES", CANCER RESEARCH, vol. 58, August 1998 (1998-08-01), pages 3732 - 3735, XP002147395 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960474B2 (en) 2000-06-28 2005-11-01 Bristol-Myers Squibb Company Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator

Also Published As

Publication number Publication date
AU6502199A (en) 2000-04-17
JP2002531061A (en) 2002-09-24
EP1117836A2 (en) 2001-07-25
WO2000018961A2 (en) 2000-04-06
CA2344550A1 (en) 2000-04-06

Similar Documents

Publication Publication Date Title
WO2000018961A3 (en) Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
MXPA02006145A (en) Method for isolation of rna from formalinfixed paraffinembedded tissue specimens.
WO1998019167A3 (en) Cell stress regulated human mhc class i gene
PT1157041E (en) ANTIBODIES FOR CANCER THERAPY AND DIAGNOSIS
WO2002099075A3 (en) Prmts as modifiers of the p53 pathway and methods of use
PT1053313E (en) OLIGONUCLEOTIDOS '' ANTISENSE '' OPTIMIZED COMPLEMENTARY SEQUENCES OF DNA METHYLTRANSFERASE
ZA971158B (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs.
MX9801264A (en) Control of cd44 gene expression for therapeutic use.
CA2429679A1 (en) Hd3a gene inducing flowering of plant and utilization thereof
WO2000053776A3 (en) Human kallikrein-like genes
ES2187648T3 (en) METHOD FOR THE ADMINISTRATION OF PHARMACOS FOR GENE THERAPY.
WO2002090925A3 (en) Polypeptides and nucleic acids associated with cancer
WO2001044282A3 (en) Bcl-g polypeptides, encoding nucleic acids and methods of use
AU5913696A (en) Methods and uses for apoptin
MXPA03000979A (en) C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF.
WO1999046374A3 (en) Human nucleic acid sequences from prostate tumour tissue
MXPA02000792A (en) Method for releasing an agent from a red blood cell.
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
AP2781A (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof
WO2000004153A3 (en) Repression of cell transformation with human pea3
WO1998051782A3 (en) Human 3-hydroxyisobutyryl-coenzyme a hydrolase
AU2347501A (en) Trp-protein-related mtr1 protein and dna sequence coding therefor
WO2002062204A3 (en) Methods for diagnosing and treating heart disease
WO1999061097A3 (en) Alpha emitting constructs and uses thereof

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 65021

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2344550

Country of ref document: CA

Ref country code: CA

Ref document number: 2344550

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999952976

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 572408

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999952976

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09806428

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1999952976

Country of ref document: EP